Ovarian cancer can no longer be considered one disease entity, but a heterogeneous group of diseases. Our understanding of its clinical and molecular complexity is improving nota‐ bly over the last decade. This is of utmost importance when it comes to determine the most adequate treatment strategy for each individual patient. Despite not being the most frequent tumor, ovarian cancer has the highest mortality rate amongst gynecological cancers. The ab‐ sence of specific symptoms and the lack of a universally and validated screening strategy leads to a delayed diagnosis, when the tumor has spread beyond the.
